Patents Assigned to Leo Pharma A/S
  • Publication number: 20060166990
    Abstract: The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
    Type: Application
    Filed: July 9, 2004
    Publication date: July 27, 2006
    Applicant: Leo Pharma A/S
    Inventors: Erik Ottosen, Anne Horneman, Xifu Liang, Soren Schou, Sophie Havez, Thoma Sabroe
  • Publication number: 20060128766
    Abstract: The invention relates to novel compounds according to formula Ia and Ib, said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases, or cancer.
    Type: Application
    Filed: December 2, 2005
    Publication date: June 15, 2006
    Applicant: Leo Pharma A/S
    Inventor: Rytter Ottosen Erik
  • Patent number: 7034015
    Abstract: The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: April 25, 2006
    Assignee: Leo Pharma A/S
    Inventors: Erik Rytter Ottosen, Anne Marie Horneman, Xifu Liang
  • Publication number: 20060014804
    Abstract: Pyridyl cyanoguanidine compounds according to formula I wherein A, R1, R2, R5, R6, X1, X2, X3, X4, Y1, Y2, Y3, Y4 and n are as indicated in the description are useful as prodrugs in human veterinary therapy of proliferative diseases such as cancers.
    Type: Application
    Filed: May 15, 2003
    Publication date: January 19, 2006
    Applicant: Leo Pharma A/S
    Inventor: Ernst Binderup
  • Publication number: 20050215588
    Abstract: Pyridyl cyanoguanidine compounds of the general formula I wherein A, X1, X2, X3, Y1, Y2, Y3, R1, R2, R5, R6 and n are as indicated in the description are suitable as prodrugs in human and veterinary therapy of proliferative diseases such as cancers.
    Type: Application
    Filed: May 15, 2003
    Publication date: September 29, 2005
    Applicant: Leo Pharma A/S
    Inventors: Ernst Binderup, Tore Duvold
  • Patent number: 6642215
    Abstract: A method of modulating the level of activated, NF-&kgr;B in cells by contacting cells with a cyanoguanidine compound of general formula I wherein n is 0, 1 or 2; each R independently represents halogen, trifluoromethyl, hydroxy, C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, nitro, cyano, amino, sulfo or carboxy groups; Q is a straight or branched, saturated or unsaturated C4-20 divalent hydrocarbon radical; X is a bond, O, S, amino, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino; A is di-(C1-4 alkoxy)phosphinoyloxy, C1-4 alkoxycarbonyl, C1-4 alkoxycarbonylamino, saturated or unsaturated C3-12 carbocyclic ring or C3-12 heterocarbocyclic ring optionally substituted with one or more R1; R1 being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, nitro, cyano, amino, carboxy, sulfo, carboxamido,
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: November 4, 2003
    Assignee: Leo Pharma A/S
    Inventors: Mogens Winkel Madsen, Lone Stengelshøj Olsen
  • Patent number: 6605742
    Abstract: Novel cyclo azaphospha hydrocarbons according to formula I are provided. The compounds are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: August 12, 2003
    Assignee: LEO Pharma A/S
    Inventors: Thomas Høyer, Morten Dahl Sørensen